These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38714910)

  • 1. Author Correction: Targeting the incretin system in obesity and type 2 diabetes mellitus.
    Ansari S; Khoo B; Tan T
    Nat Rev Endocrinol; 2024 Aug; 20(8):501. PubMed ID: 38714910
    [No Abstract]   [Full Text] [Related]  

  • 2. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
    Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes.
    Tan Q; Akindehin SE; Orsso CE; Waldner RC; DiMarchi RD; Müller TD; Haqq AM
    Front Endocrinol (Lausanne); 2022; 13():838410. PubMed ID: 35299971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the incretin system in obesity and type 2 diabetes mellitus.
    Ansari S; Khoo B; Tan T
    Nat Rev Endocrinol; 2024 Aug; 20(8):447-459. PubMed ID: 38632474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel incretin-based agents and practical regimens to meet needs and treatment goals of patients with type 2 diabetes mellitus.
    Garber AJ
    J Am Osteopath Assoc; 2011 Jul; 111(7 Suppl 5):S20-30. PubMed ID: 21813733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus.
    Nisal K; Kela R; Khunti K; Davies MJ
    BMC Med; 2012 Nov; 10():152. PubMed ID: 23198896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.
    Campbell RK
    Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity.
    Opinto G; Natalicchio A; Marchetti P
    Arch Physiol Biochem; 2013 Oct; 119(4):170-8. PubMed ID: 23859800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incretin hormones: Their role in health and disease.
    Nauck MA; Meier JJ
    Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective.
    Michałowska J; Miller-Kasprzak E; Bogdański P
    Nutrients; 2021 Jan; 13(2):. PubMed ID: 33503878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving glucagon-like peptide-1 dynamics in patients with type 2 diabetes mellitus.
    Freeman JS
    J Am Osteopath Assoc; 2012 Jan; 112(1 Suppl 1):S2-6. PubMed ID: 22267300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients.
    Muscelli E; Mari A; Casolaro A; Camastra S; Seghieri G; Gastaldelli A; Holst JJ; Ferrannini E
    Diabetes; 2008 May; 57(5):1340-8. PubMed ID: 18162504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
    Cornell S
    J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretin effect determines glucose trajectory and insulin sensitivity in youths with obesity.
    Galderisi A; Tricò D; Lat J; Samuels S; Weiss R; Van Name M; Pierpont B; Santoro N; Caprio S
    JCI Insight; 2023 Nov; 8(22):. PubMed ID: 37847560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks.
    Chai S; Yu S; Yang Z; Wu S; Gao L; Wang H; Zhang Y; Zhan S; Ji L; Sun F
    BMJ Open Diabetes Res Care; 2019; 7(1):e000728. PubMed ID: 31641525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Levels of Incretin Hormones - GLP-1 and GIP in Patients with Type 1 Diabetes Mellitus.
    Stanchev PE; Orbetzova MM; Terzieva DD; Davcheva D; Iliev DA; Petrov SV; Koleva DI; Nonchev BI
    Folia Med (Plovdiv); 2019 Mar; 61(1):76-83. PubMed ID: 31237842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incretin mimetics and enhancers for the treatment of type 2 diabetes mellitus.
    Ruige JB
    Acta Clin Belg; 2008; 63(2):81-5. PubMed ID: 18575047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact?
    Aulinger BA; Vahl TP; Prigeon RL; D'Alessio DA; Elder DA
    Am J Physiol Endocrinol Metab; 2016 May; 310(9):E774-81. PubMed ID: 26979523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond.
    João AL; Reis F; Fernandes R
    Obes Rev; 2016 Jul; 17(7):553-72. PubMed ID: 27125902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laparoscopic sleeve gastrectomy versus single anastomosis (mini-) gastric bypass for the treatment of type 2 diabetes mellitus: 5-year results of a randomized trial and study of incretin effect.
    Lee WJ; Chong K; Lin YH; Wei JH; Chen SC
    Obes Surg; 2014 Sep; 24(9):1552-62. PubMed ID: 24965545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.